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There is an obvious, signiﬁcant, and diachronic reduction of the prevalence of HBV infection in Greece, concerning the general
population as well as some traditionally high-risk groups, mainly as a result of constant informing and the widespread initiation
of preventive and prophylactic measures, as well as the improvement of health care services. Nevertheless, there are special groups
and populations (economical refugees, religious minorities, HIV-positive patients, abroad pregnant women, prostitutes, etc.) who
represent sacs of high HBV endemicity and need epidemiological supervision and intervention, in order to limit the spread of the
infection and to further improve the existing epidemiological data.
Copyright © 2008 Konstantinos D. Pantazis et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
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Hepatitis B virus (HBV) infection is a major public health
problem worldwide, as more than 2 billion people have been
infected, whereas more than 350 million present chronic
HBV infection. It is estimated that a signiﬁcant proportion
(15–40%) of chronic HBV infected patients develop liver cir-
rhosis, liver failure, and primary hepatocellular carcinoma
(HCC), making chronic hepatitis B one of the 10 major
causes of death worldwide [1].
The prevalence of the infection varies among diﬀerent
areas of the world and among special populations within
the same area. About 45% of the world population lives in
countries in which HBV infection is hyperendemic (South-
Eastern Asia and sub-Saharan Africa), where the percentage
of hepatitis B surface antigen (HBsAg) seropositivity out-
ranges 8% of the total population and the percentage of vi-
ral exposure varies between 70% and 90%. In these coun-
tries, HBV infection is vertically transmitted usually dur-
ing the perinatal period and horizontally during the in-
fancy and early childhood age, leading to extremely high
rates of chronic HBV infection and preserving the reservoir
of chronic hepatitis B patients worldwide [2, 3]. Southern
countries of Central and Eastern Europe as well as those of
the Mediterranean basin, the Amazon’s sink, Middle East, and
Northern Africa are regions of medium HBV infection sero-
prevalence (HBsAg seropositivity between 2–7%), whereas
countries of North-Western Europe and North America are
considered to be countries with low HBV endemicity (HB-
sAg seropositivity < 2%). In these countries, the infection is
basically transmitted horizontally during the adolescent and
early adult period, mainly by high-risk sexual activity [4].
Moreover, the annual incidence of HCC is extremely
high in hyperendemic regions of HBV infection (10–150
cases/100.000 people per year) compared to regions of lower
prevalence (1–3 cases of HCC/100.000 people per year), a
ﬁnding that supports the causative relationship of HBV and
HCC. The primary HCC is one of the most common tu-
m o u r s( 5 t hi nf r e q u e n c yw o r l d w i d e )a n di sconsidered re-
sponsible for 300000–500000 deaths annually, representing
the 3rd most common cause of death in the hyperendemic
countries of HBV infection [5].
Patients with chronic hepatitis B have a threefold prob-
ability to die within a decade compared to general popula-
tion, mainly by causes directly related to chronic liver dis-
ease(HCC, hepatocellularfailure,varicealbleeding, etc.)[6].
Regarding the cost of patients’ hospitalization, it seems that
patients with chronic HBV infection spend more time in
the hospital and need more specialized and expensive in-
hospital treatment compared to the general population. An
epidemiological and economotechnical study from a set area
of Scotland showed a signiﬁcant diﬀerence in the duration of2 Gastroenterology Research and Practice
hospitalization and the mean cost of treatment, as well as in
the number of admissions and readmissions of patients with
chronic HBV infection, compared to the control group [6].
The annual cost of treating patients with chronic HBV infec-
tion has been retrospectively estimated and seems to signiﬁ-
cantly diﬀerentiate between patients in procirrhotic or com-
pensated cirrhotic stages of the disease under treatment and
those who exhibit decompensated cirrhosis, especially when
they undergo liver transplantation procedure. Even the pal-
liative treatment of end-stage HCC costs higher than long-
term treatment of early stages of the disease [7].
A signiﬁcant decline of the incidence of acute hepatitis
B cases (67%) has been observed in the USA after 1990, es-
pecially among high-risk groups (such as intravenous drug
users, homosexual men, and health care professionals), ac-
cording to Center of Diseases Control (CDC). Widespread
vaccination programs, predelivery evaluation of pregnant
women and passive-active immunoprophylaxis of infants
born from chronic HBV infected mothers, blood donors
control, and immunization of the majority of health care
professionals, children and teenagers have resulted in that
decline. Considering the lack of those preventive and pre-
caution measures in many hyperendemic countries of the
world and the massive immigration observed in the last ﬁf-
teen years, mainly from countries of median or high preva-
lence of the infection to countries of low HBV prevalence,
the epidemiological data of HBV infection seem to be signif-
icantly modiﬁed nowadays.
In Greece, the existing published epidemiological data
are diﬃcult to be representative to the general population
data, mainly because they are referred to speciﬁc popula-
tions (blood donors, religious-ethnic minorities, economic
immigrants, soldiers, children, pregnant women) or high-
risk groups (prisoners, drug users, haemodialysis patients,
HIV, prostitutes, etc.) over- or underestimating the problem.
The National Institute of Employment and the National Sta-
tistical Service reported that the number of recorded foreign
immigrants in Greece at the inventory of 2001 was approx-
imately 800000 (7.2% of recorded Greek population) and
the majority of them (65%) came from Albania, a country
of high endemicity of HBV infection.
In general, the comparison of studies from the early 70s
with others from the late 80s shows a signiﬁcant decline of
HBV prevalence in Greece of about 50–80%. Studies on mil-
itary recruits exhibit a signiﬁcant decline of HBsAg preva-
lence, from 4% in 1973 to 0.95% in 1999, mainly due to the
modiﬁcation of socioeconomical and medical practice pa-
rameters and to the signiﬁcant increase of successfully vac-
cinated people [8, 9]. General population published data are
limited in Greece whereas the best-studied group is that of
blood donors. In the larger cohort of blood donors stud-
ied for 6 consecutive years in Athens, the mean prevalence
of HBsAg was 0.84% [10]. A study of a large population of
blood donors in Crete island for 5 consecutive years revealed
that the mean prevalence of HBsAg (0.4%) was signiﬁcantly
lower than the one reported from other compartments of our
country [11]. Equally, low percentages of HBsAg prevalence
were observed in children of school age and teenagers of a
rural population of Crete (0.33%) and in high-risk hospital-
ized patients (2.66%), reﬂecting partially the epidemiolog-
ical data of the general population of the island [12, 13].
A signiﬁcant decline of HBsAg prevalence by 2.15% and
of the percentage of HBV exposure by 22.6% are reported
in the ﬁrst published study concerning the general popu-
lation, in the region of South-Western Greece, whereas in
the region of Epirus in a 3-year prospective study of blood
donors, the HBsAg seropositivity was of 0.85%, relatively
higher than the one reported from other compartments of
Greece [14, 15].
The immigration of populations from countries of high
endemicity of the infection seems to contribute signiﬁcantly
to the rapid modiﬁcation of epidemiological data, espe-
cially in areas bearing the high burden of immigrants. In
a serological control of 1020 refugees from South Albania
who came and work in Ioannina region, the percentages of
HBsAg seropositivity and HBV exposure were 22.2% and
70.6%, respectively. Moreover, a signiﬁcant proportion of
chronic HBV infected Albanian patients were also hepatitis B
e antigen-positive [HBeAg(+)] (21.1%) and 12.7% of them
were chronic hepatitis D virus (HDV) infected, representing
apopulation ofhigh infectivity regarding viralhepatitis [16].
Data regarding immigrants living in Athens showed that the
prevalenceofHBsAgwassigniﬁcantly high(15.4%)especially
among Albanian and Asian refugees [17]. Likewise, signiﬁ-
cant diﬀerences of the prevalence of HBV infection are re-
ported in the religious minority of Thrace moslems compar-
ing to Greeks from formal Soviet Union who live in the same
area and the native habitants of Thrace (9.3% versus 4.3%
versus 3.4%, respectively), revealing a population of high en-
demicity of HBV infection within our country [18].
Perinatal (vertical) transmission is one of the most com-
mon ways of HBV infection dispersion, mainly in hyperen-
demic areas of the world and seropositive pregnant women
and their neonates represent the basic target groups for the
elimination of vertical transmission, which preserves the
mainreservoirofchronicHBVinfectedpatients.Inthelarger
group of women at reproductive age studied in Greece, the
mean prevalence of HBsAg was 1.15%, but was signiﬁcantly
higher among women of Albanian (5.1%) and Asian origin
(4.2%) compared to Greek women (0.29%). The vast ma-
jority (71.34%) of HBsAg-positive women were of Albanian
origin and about a third of them exhibited signiﬁcant viral
replication at perinatal period [19].
Intravenous drug users and prisoners are also high-risk
groups for viral hepatitis who were studied epidemiologically
in our country. In a study of 544 prisoners who were intra-
venous drug users concomitantly, 6.5% of them exhibited
HBsAg-positivity whereas among prisoners for sexual of-
fencesthepercentageofHBsAg-positivitywashigherenough
(13%) [20, 21]. The widespread of HBV infection in the
Greek drug-users community observed in the past decade,
according to published studies [22]s e e m st ob ec h a n g e d
nowadays.Inanourrecentlypublishedstudy,weinvestigated
the presence of serological markers of HBV infection in in-
travenous drug users (IVDU) with chronic hepatitis C virus
(HCV) infection and the results were correlated to the time
of drug usage initiation. We found that drug use initiation
before 1992 was signiﬁcantly related to HBV exposure whileKonstantinos D. Pantazis et al. 3
the vast majority of relatively newer drug users (drug initia-
tion after 1992) were HBV seronegatives [23].
In Greek oncologic patients with solid tumors, the per-
centages of HBsAg-seropositivity were 5.3% and those of
HBV exposure 44%, while a proportion of them (14%) had
clinical and/or biochemical exacerbation of liver disease dur-
ing the chemotherapy schedule; this percentage is expected
to be much higher in patients with haematological malig-
nancies, with or without steroid administration according to
the international literature [24]. Furthermore, signiﬁcantly
higherprevalenceofHBVinfectionisobservedinchronical-
coholic patients—with or without established liver disease—
compared to healthy blood donors or nonalcoholic hospi-
talized patients, which is ascribed to their speciﬁc and some
times unexpected behavior [25].
Chronic liver disease due to coexisting chronic viral hep-
atitis B and/or C as well as a consequence of hepatotoxic-
ity of the antiretroviral therapy is one of the most impor-
tant factors of morbidity and mortality of human immun-
odeﬁciency virus- (HIV-) infected patients, since the classic
opportunistic infections and the complications of severe im-
munodeﬁciency have been signiﬁcantly diminished. In HIV-
seropositive patients the probability of chronic HBV infec-
tion and chronic liver disease after exposure to HBV is ex-
tremely high and is characterized by very high levels of vi-
raemia (serum HBV-DNA) and extremely low percentages
of spontaneous loss and/or seroconversion of HBeAg [26].
About 13% of a group of HIV-positive patients, mainly ho-
mosexual men (68.5%), were HBsAg-positive and the per-
centage of their exposure to HBV infection was 67.4%, rep-
resenting a high-risk group for viral hepatitis [27]. In a co-
hort study in Greece, regarding 737 HIV-positive patients,
the percentage of HBsAg-seropositivity was 12.1% while the
majority of HIV/HBV coinfected patients (60.9%) were also
HBeAg-positive and they exhibited extremely high levels of
HBV viral load, suggesting the direct uptake of preventive
measures for this high-risk group, in order to protect its
health and the public health in general [28].
An obvious trend of reduction of the HBV prevalence
is observed in other traditionally high-risk groups, such
as prostitutes, since the percentage of HBsAg-seropositivity
(11%) at the early 80s has been reduced to 3.3% in the late
90s; these data need to be reevaluated because of the high
percentage of people traﬃcking for sexual reasons, mainly
fromcountriesofmedian-highHBVprevalencetoourcoun-
try, who are not reported or sanitary controlled and are
thoughttorepresentthemostsigniﬁcantcauseofHBVtrans-
mission in our days [29, 30]. Data from a study of the De-
partment of Public Order were presented in daily press and
according to conservative calculations there are more than
14000 people who are illegally sexually prostituted in our
country.
Finally, the professional exposure in the health care
worker ﬁeld has been studied since the 70s, where the per-
centagesofHBsAgseroprevalencewere2.4%formedicalstu-
dents and 4.6% for nursing staﬀ. In a recent study from Hip-
pokration Hospital of Athens including 400 nursing staﬀ, the
percentage of HBsAg-seropositivity was 1.25% and the HBV
exposure rate was 16%, but only 61% of that high-risk group
were eﬃciently vaccinated, so there is a signiﬁcant percent of
population unprotected for various but nonaccepted reasons
[31].
In conclusion, although there is an obvious, signiﬁcant,
and diachronic reduction of the prevalence of HBV infection
in Greece, concerning the general population as well as some
traditionally high-risk groups, mainly as a result of constant
informing and the widespread initiation of preventive and
prophylactic measures as well as the improvement of health
care services, there are special groups and populations (eco-
nomicalrefugees,religiousminorities,HIV-positivepatients,
abroadpregnantwomen,prostitutes,etc.)whorepresentsacs
of high-HBV endemicity and need epidemiological supervi-
sion and intervention, in order to limit the spread of the in-
fection and to further improve the existing epidemiological
data.
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